Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in MEN1 Patients
NCT05605587Terminated
- Sponsor
- University Hospital Basel
- Start
- May 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of leflunomide in Multiple endocrine neoplasia type 1 (MEN1), sponsored by University Hospital Basel. Primary endpoint: Effect on MEN1-associated functional and non-functional tumors at 6 months. Started May 2023; status: terminated.
02
Drugs
leflunomide
03
Conditions
Multiple endocrine neoplasia type 1 (MEN1)
Beyond the preview
Go deeper on NCT05605587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605587.